Breaking News | YHLO Achieves Full IVDR CE Certification for the Blood Bank Panel 🎉— the First in China 🇨🇳🌍
Breaking News!!! We are thrilled to share a major milestone in YHLO's global regulatory journey that we have got the latest Class D IVDR CE certificate for our HIV assay! With this approval, YHLO has now achieved full IVDR CE certification for the entire Blood Bank Panel—including HIV, HBV(HBsAg, Anti-HBs, HBeAg, Anti-HBe, Anti-HBc), HCV, and Syphilis(Anti-TP).
This achievement makes YHLO the first company in China — and among the first globally — to obtain full IVDR CE certification for the Blood Bank panel.
Founded in 2008, YHLO is a national high-tech enterprise and specialized in R&D, production and sale of in vitro diagnostic (IVD) instruments and reagents. With our committed innovation, nowadays our multiple products have entered more than 120 countries.
YHLO will continue working hand-in-hand with glogal partners to build a healthier, better future together.
Attachments:
Previous
MORE NEWS
n November 18, 2025, YHLO’s 2025 Global Core Distributors Conference was successfully held in Düsseldorf, Germany. Under the theme “Academia-Driven, Shared Value,” the meeting brought together representatives from more than 30 core distributors worldwide. YHLO’s founder, Mr. Deming Hu, and Chairman, Mr. Kunhui Hu, led the company’s executive team to attend and discuss strategic development with partners.
2025-11-20
YHLO Secures Approval for the World’s First sCD146 CLIA Assay
YHLO has obtained approval from the Guangdong Medical Products Administration for its soluble CD146 (sCD146) CLIA assay, marking a major milestone in central nervous system (CNS) disease diagnostics. YHLO is now the first company worldwide to offer an sCD146 test for cerebrospinal fluid, bringing its total CLIA assay portfolio in China to 173.
2025-11-18
Add: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China
